LVTX - Nilai Akuntansi saben Saham Lava Tx

Simbol resmi perusahaan Lava Tx (LVTX)

LAVA Therapeutics N.V. (LVTX) is shielded from macroeconomic shocks due to stable demand for biotechnology. The estimated book value per share illustrates net asset dynamics, where the value of 0.48 represents the most recent figure. The business foundation is the GAMA platform, which creates high barriers to entry for competitors. Growth prospects are based on the market launch of innovative bispecific antibodies for cancer treatment.

LVTX Nilai Aset Bersih saben Saham LAVA Therapeutics N.V. (04.07.2022 - 06.12.2025)

LVTX (LAVA Therapeutics NV): rincian analitis lan laporan miturut indikator

- rega saham lan prakiraan rega para ahli:
Kutipan saham Lava Tx|LVTX - Rega prakiraan analis
- statistik kapitalisasi pasar:
Biji pasar LAVA Therapeutics N.V.|LVTX - Nilai Bisnis
- indikator nilai aset resik miturut neraca:
Aset Bersih saben Siji Saham LAVA Therapeutics|LVTX - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku lavatherapeutics.com|LVTX - Total Aset Bisnis
- indikator beban utang lan likuiditas:
Total Utang marang Modal LAVA Therapeutics N.V.|LVTX - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Lava Tx|LVTX - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku LAVA Therapeutics N.V.|LVTX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan LAVA Therapeutics|Rasio cepet lavatherapeutics.com
- data bathi lan kelipatan valuasi:
LVTX - Bathi resik taunan
Analisis dhasar perusahaan:LVTX - lavatherapeutics.com
Produk sing diprodhuksi Lava Tx

Book value per share determines the portion of equity per security, reflecting the actual value of the company's net assets. For LAVA Therapeutics N.V. (LVTX), analyzing the book value per share allows for an assessment of the company's financial stability against the backdrop of costly gamma-delta T-cell developments and risks associated with the clinical trial results of bispecific antibodies.

Analisis pesaing LAVA Therapeutics N.V.

IBRX: Nilai Akuntansi saben Saham|Immunocore Corp - Rega Buku Saham|JANX (Janux Therapeutics) - Nilai Akuntansi saben Saham|Ekuitas saben Saham RCUS|Aset Bersih saben Siji Saham Zymeworks|Nilai Aset Bersih saben Saham Tango Therapeutics Inc TNGX|Aset Bersih saben Siji Saham Iovance (IOVA)|Immatics Biotechnologies - Ekuitas saben Saham|Nilai Buku saben Saham XNCR (Xencor, Inc.)|CMPX - Nilai Akuntansi saben Saham|REPL - Aset Bersih saben Siji Saham|Nilai Aset Bersih saben Saham Lyell|Innate Pharma, S.A. (IPHA) - Aset Bersih saben Siji Saham|PYXS (Pyxis Oncology) - Aset Bersih saben Siji Saham|Aset Bersih saben Siji Saham Compugen Ltd|Nilai Aset Bersih saben Saham iobiotech.com IOBT|Nilai Buku saben Saham STRO|MiNK Therapeutics Inc. (INKT) - Nilai Buku Siji Saham|Werewolf Therapeutics, Inc. - Nilai Akuntansi saben Saham|Immix Biopharma Inc. (IMMX) - Nilai Aset Bersih saben Saham|ALXO: Nilai Akuntansi saben Saham|Nilai Akuntansi Saham CUE (cuebiopharma.com)|PDSB: Nilai Buku saben Saham|SONN - Aset Bersih saben Saham|Aset Bersih saben Siji Saham MAIA Biotechnology Inc|Nilai Akuntansi saben Saham Liminatus (LIMN)|Aset Bersih saben Siji Saham NextCure, Inc. (NXTC)|Nilai Akuntansi saben Saham leaptx.com LPTX|Intensity Therapeutics, Inc. - Nilai Akuntansi saben Saham|Nilai Buku saben Saham Sensei Biotherapeutics Inc SNSE|TOVX - Aset Bersih saben Siji Saham|GRTS (Gritstone bio, Inc.) - Ekuitas saben Saham|Kineta, Inc. (KA) - Aset Bersih saben Siji Saham|Nilai Aset Bersih saben Saham neximmune.com (NEXI)|Nilai Akuntansi saben Saham TSBX|VCNX - Nilai Buku Siji Saham|Nilai Akuntansi saben Saham HARP (Harpoon Tx)